growth is expected from the rapid POC test for TpP,
as well as for our existing FDA approved ELISA format.
In fact the total potential market for TpP is so large
that the Company is pursuing licensing agreements
with large diagnostic/ pharmaceutical companies to
help reach the appropriate segments.
Fibrinogen is a recognized risk factor for cardiovascular
disease and is considered to be as important, if not
more than, cholesterol. With the advent of new drugs
to lower fibrinogen levels, the Company's Functional
Intact Fibrinogen (FiF) test, which offers a quantitative
measurement of fibrinogen, becomes increasingly important.
ABS intends to pursue additional clinical evaluation
for this test in 1999.
Further growth is expected from contract arrangements,
similar to the Trevigen, Inc. deal, with the Company's
Antigen Free technology, which has the capability
to produce high affinity monoclonal antibodies that
cannot be produced by conventional means.
ABS through its Stellar Bio Systems division continues
to develop novel diagnostic tests for infectious diseases,
such as herpes virus 8, an opportunistic virus implicated
in Karposi's sarcoma.
In addition, ABS is pursuing synergistic acquisitions
in both diagnostic and therapeutic fields in line
with the Company's dual strategy.